EurekaMag.com logo
+ Site Statistics
References:
53,517,315
Abstracts:
29,339,501
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on Google+Follow on Google+
Follow on LinkedInFollow on LinkedIn

+ Translate

Comparative bioavailability of two tablet preparations of metronidazole



Comparative bioavailability of two tablet preparations of metronidazole



International Journal of Clinical Pharmacology Research 8(4): 227-229



In a randomized cross-over study, eight healthy volunteers received single 200 mg doses of metronidazole tablets (as either the May and Baker or Servipharm preparation) after an overnight fast. The bioavailability of these two preparations did not differ significantly as judged from the peak plasma concentration, time to peak plasma concentration and area under the plasma concentration-time curve. Metronidazole was found to have a plasma clearance of 1.05 .+-. 0.14 (s.d.) and 0.98 .+-. 0.17 ml min-1 kg-1, a plasma terminal half-life of elimination of 9.15 .+-. 1.01 and 10.35 .+-. 1.59 h, and an apparent volume of distribution of 0.83 .+-. 0.06 lkg-1 (the values obtained with the May and the Baker preparation being shown before the Servipharm preparation in each case).

(PDF 0-2 workdays service: $29.90)

Accession: 001780715

Download citation: RISBibTeXText

PMID: 3182111



Related references

Comparative bioavailability study of two ketoconazole tablet preparations. Medical Journal of Malaysia 54(4): 482-486, 2000

Comparative bioavailability study of two atenolol tablet preparations. Drug Development and Industrial Pharmacy 25(3): 357-360, 1999

Comparative bioavailability of two tablet preparations of diltiazem in healthy volunteers. Arzneimittel-Forschung 42(1): 25-27, 1992

Comparative bioavailability of two enteric-coated tablet preparations of diclofenac sodium. International Journal of Clinical Pharmacology Research 7(4): 239-242, 1987

Comparative bioavailability study of two controlled-release pentoxifylline tablet preparations. Drug Development and Industrial Pharmacy 26(7): 803-807, 2000

Bioavailability and pharmacological effects of two slow-release theophylline preparations: intrasubject tablet-to-tablet variability. Journal of Asthma 23(3): 113-122, 1986

Effect of surfactant on the bioavailability of metronidazole from tablet formulation. Indian Journal of Pharmaceutical Sciences 46(3): 118-120, 1984

Effect of surfactant on the bioavailability of metronidazole from tablet formulation Dogs. Indian journal of pharmaceutical sciences 46(3): 118-120, 1984

Comparative kinetics and bioavailability of bioadhesives containing or not-containing ketoprofen tablet formulations relative to conventional tablet in humans. Pharmaceutical Research (New York) 14(11 SUPPL ): S249, 1997

Bioavailability of two tablet preparations of carbimazole in man. Clinical and Experimental Pharmacology & Physiology 6(5): 479-485, 1979

Bioavailability of a valproic acid preparation. The relative bioavailability of enteric-resistant valproic acid preparations in tablet form with simultaneously administered tetradeuterated valproic acid as the bioavailability reference. Arzneimittel-Forschung 36(7): 1118-1122, 1986

Comparative bioavailability of lornoxicam as single doses of quick-release tablet, standard tablet and intramuscular injection: a randomized, open-label, crossover phase I study in healthy volunteers. Clinical Drug Investigation 28(6): 345-351, 2008

Relative bioavailability studies on two tablet preparations of ofloxacin. Archives of Pharmacal Research (Seoul) 15(3): 208-210, 1992

Comparative bioavailability of d-pseudoephedrine from a conventional d-pseudoephedrine sulfate tablet and from a repeat action tablet. Journal of International Medical Research 10(2): 126-128, 1982

Bioavailability study of drotaverine from capsule and tablet preparations in healthy volunteers. Arzneimittel-Forschung 54(5): 298-302, 2004